CHARGED ALPHATMFrontier AI stock research

ALC · NYSE

Alcon Inc.

Medical Instruments & Supplies · Switzerland

USD 74.110.6% daily changeQuote 2026-11-17 · USD
Market cap (USD)
US$35.60B
Trailing P/E
54.09x
Forward P/E
18.97x
Quarterly revenue growth
4.7%
Trailing net margin
6.1%
Indicated dividend yield
0.5%

Snapshot 2026-11-18 · Latest financial period 2026-09-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.

Company background

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. In addition it also develops and commercializes therapies for chronic eye diseases, focusing on encapsulated cell therapy platforms for ocular conditions. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Company website

Q2 2026

Go beyond the headline.

Alcon (ALC) Q2 2026: A $402M Write-Off And A Lens Line Growing 1%

Published 2026-08-13

Comparable businesses

ALC peer comparison

Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.

Comparison stocks

Market metrics · missing or inapplicable values shown as —
MetricALCAlcon Inc.Snapshot 2026-11-18Financial period: 2026-09-30RMDResMed Inc.Snapshot 2026-11-18Financial period: 2026-09-30WSTWest Pharmaceutical Services, Inc.Snapshot 2026-11-18Financial period: 2026-09-30Peer medianSimilar-size peers only
Market capMarket value, converted to USDUS$35.60BUS$33.46BUS$28.85BUS$31.15Bn=2
Forward P/EProvider forward earnings estimate18.97x17.98x39.84x28.91xn=2
EV / EBITDAEnterprise value / trailing EBITDA16.36x15.54x29.85x22.70xn=2
Revenue growthLatest quarter vs prior-year quarter4.7%5.9%8.7%7.3%n=2
Operating marginLatest reported quarter12.9%34.0%22.9%28.4%n=2
Free cash flow yieldTrailing cash flow / market cap3.6%3.9%1.2%2.5%n=2
Net debt / EBITDANet debt / trailing EBITDA1.48x-0.19x-0.16x-0.17xn=2
Debt / equityTotal debt / positive book equity0.25x0.10x0.11x0.10xn=2
Trailing P/ETrailing twelve-month earnings54.09x21.66x46.48x34.07xn=2
Price / bookPrice / positive book equity per share1.64x5.62x9.74x7.68xn=2
EV / salesEnterprise value / trailing revenue3.56x5.77x8.45x7.11xn=2
Earnings growthLatest quarter vs prior-year quarter12.5%23.2%57.3%40.2%n=2
Gross marginTrailing twelve months57.9%61.8%37.6%49.7%n=2
Net marginTrailing twelve months6.1%27.8%18.8%23.3%n=2
Return on equityProvider trailing return; positive equity only3.0%26.4%21.2%23.8%n=2
Free cash flow marginTrailing free cash flow / revenue11.6%22.6%10.2%16.4%n=2
Dividend yieldIndicated annual dividend / price0.5%1.1%0.3%0.7%n=2
Earnings payoutProvider trailing dividend payout25.6%22.4%9.9%16.1%n=2
Current ratioCurrent assets / current liabilities2.50x2.65x2.82x2.73xn=2
BetaProvider historical market sensitivity0.720.761.140.95n=2

Choose a comparison stock

Search covered companies, or search all listed stocks.

Comparison methodology & limitations

Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.

Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.

Reported performance

Financial trends

Reporting period
Financial history
Chart style
Comparison stocks

Financial statements load separately from the research page.

Market context

Valuation & price history

Adjusted closing price

Price history

Price history loads separately.

Earnings-multiple scenario

Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.

Starting assumptions, when available, use provider forward estimates as of 2026-11-18. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.

THE RESEARCH RECORD

Research history for ALC

All available reporting periods
Q2 20262026-08-13

Reported figures

Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.